Intradermal administration of Mallein Veterinary Grade API as a sterile aqueous solution remains the reference diagnostic procedure for glanders in equids under the OIE Terrestrial Manual. The bulk antigen is diluted in preservative-free phosphate-buffered saline. Release pH is held between 6.5 and 7.5 according to USP <791> or Ph. Eur. 2.2.3 because acidic conditions below 6.0 accelerate protein aggregation and reduce the induration reaction. Finished vials are single-dose Type I borosilicate glass sealed with bromobutyl rubber stoppers. Sterility is confirmed by direct transfer to fluid thioglycollate medium and soybean-casein digest medium under USP <71> or Ph. Eur. 2.6.1 with incubation at 30–35 °C and 20–25 °C for not less than 14 days. Bacterial endotoxin is controlled using the Limulus amebocyte lysate method of USP <85> or Ph. Eur. 2.6.14. The release criterion is derived from the approved regulatory file and may vary between 2 EU mL^-1 and 5 EU mL^-1 for diagnostic biologicals in some jurisdictions, though stricter limits often apply to injectable veterinary products. Osmolality is adjusted with sodium chloride to 270–330 mOsm kg^-1 using USP <785> or Ph. Eur. 2.2.35. Particulate matter is assessed by light obscuration under USP <788> for containers with nominal volume below 100 mL. On production filling lines, rotary piston pumps can generate shear at flow rates above manufacturer-rated limits. This shear increases subvisible particle counts and reduces the visible response in the intradermal test. The diagnostic read is performed at 24 h and 48 h after injection by measuring subcutaneous swelling with a caliper. Interpretation depends on batch-specific positive-control antigen from the national reference laboratory. Cross-reactivity from mycobacterial culture media components is minimized by ultrafiltration through 10 kDa polyethersulfone membranes with constant-volume diafiltration. Published data for this specific configuration is limited, so each production batch must be tested against a panel of negative control sera.

When Ophthalmic Diagnostic Solution Is Used in Field Glanders Screening

Field screening programs deploy the ophthalmic route when animal handling infrastructure cannot safely support intradermal injection. Ophthalmic application of Mallein Veterinary Grade API requires a lower antigen load than intradermal injection because the conjunctival mucosa is thinner and contains a dense network of dendritic cells. The solution is formulated as a sterile, isotonic, preservative-free liquid in low-density polyethylene dropper bottles or Type I glass dropper vials. The pH target is 6.4–7.4 by USP <791> or Ph. Eur. 2.2.3. Values below 6.0 cause transient epithelial irritation, while values above 7.8 reduce antigen stability during tropical field storage. Osmolality is adjusted to 280–320 mOsm kg^-1 under USP <785>. Hypotonic formulations below 260 mOsm kg^-1 induce reflexive lacrimation and shorten ocular contact time, reducing test sensitivity. Filling is performed under a nitrogen overlay to limit oxygen-mediated degradation of the protein fraction in the headspace. Sterility is demonstrated by membrane filtration of a 10 mL sample through a 0.45 µm gridded membrane and transfer to two media as defined in USP <71> or Ph. Eur. 2.6.1. Bacterial endotoxin limits are established in the regulatory dossier because recombinant LAL reagents may under-report endotoxin in some biological matrices. The ophthalmic test is read at 24 h and 48 h by inspecting conjunctival hyperemia, purulent discharge, and eyelid edema. A positive reaction requires correlation with the batch-specific positive control. Production experience shows that bottle capping torque above 20 N m can generate polymer particulates from polyethylene closures. These particulates must be monitored by the particulate matter method of USP <789> if visible inspection is passed. The ophthalmic grade is not interchangeable with the intradermal grade because diluent composition and fill volume affect antigen presentation kinetics.

In markets where the cold chain is discontinuous, Mallein Veterinary Grade API is supplied as a lyophilized powder for reconstitution in sterile diluent. The sterile bulk solution is filled into 2 mL or 5 mL Type I glass vials with a lyophilization stopper in the vented position and frozen at a ramp rate controlled to avoid large ice crystal formation. Large ice crystals produce a collapsed cake after primary drying. Freeze-drying microscopy is used to determine the collapse temperature. Primary drying is conducted at a product temperature below this collapse point, typically between −25 °C and −10 °C for protein-containing veterinary biologics. Chamber pressure is maintained between 50 mTorr and 100 mTorr during primary drying. Secondary drying is extended until residual moisture is not more than 3.0% w/w by Karl Fischer titration under USP <921> or Ph. Eur. 2.5.12. The dried cake must be pale beige to white, uniform, and free of shrinkage. Collapse at the vial edge is a common production-scale failure caused by radiant heat transfer from the shelf walls and is controlled by placing edge vials as internal controls. Reconstitution with sterile water for injection produces a solution with pH 6.5–7.5 and slight opalescence. This opalescence is acceptable if the subvisible particle count passes USP <788>. After reconstitution, the diagnostic solution should be used within 2 hours if stored at 15–25 °C because proteolytic activity from residual components increases over time. The lyophilized presentation is not equivalent to a simple dried powder. The freeze-drying cycle must be revalidated when the fill volume changes by more than 10% because cake thickness alters heat and mass transfer. Published data for this full-scale lyophilization configuration is limited; therefore cycle performance is verified with thermocouple-instrumented vials and post-dry residual moisture mapping.

Why Does Complement Fixation Test Antigen Require Magnesium and Calcium Titration Before Release?

Complement fixation uses Mallein Veterinary Grade API as a soluble antigen to detect anti-Burkholderia mallei antibodies in equine serum. The reaction depends on the classical complement pathway, which requires free divalent cations. Standard veronal-buffered saline diluent contains 0.5 mM magnesium chloride and 0.15 mM calcium chloride, as specified in current immunological laboratory procedures aligned with the OIE Terrestrial Manual. Excess magnesium above 1.0 mM can stabilize complement in the absence of antigen–antibody complexes, producing anticomplementary background. Calcium chelation by EDTA-containing blood collection tubes is a common field failure that reduces sensitivity. The antigen is titrated in a checkerboard assay against known positive and negative equine sera. The working dilution is selected at the highest antigen concentration that does not bind complement alone. Hemolytic serum and guinea pig complement are titrated to 50% hemolysis units. The test is incubated at 4 °C for 18 hours before adding sensitized sheep erythrocytes. The API batch must be free of anticomplementary activity. This is verified by running antigen-only controls at the top three concentrations. Potency is assigned against an OIE reference preparation. Release tests include specificity against a panel of sera from uninfected equids originating from glanders-free zones. The complement fixation antigen is often supplied as a liquid at 2–8 °C with a shelf life not exceeding 12 months. Repeated freeze-thaw cycles are prohibited because they cause loss of antigenic reactivity. Production-scale clarification by depth filtration through 0.2 µm filters can remove lipoproteins that cause non-specific hemolysis. Excessive filtration through positively charged membranes may bind the antigen and reduce signal intensity. Published data for this specific binding matrix is limited, so filtrate potency must be compared with the unfiltered bulk whenever filter changeover occurs.

Potency Calibrator Preparation and Comparative Diluent Effects

The API is employed as an in-house potency calibrator for intradermal and serological diagnostic methods. A representative lyophilized batch is assigned a potency in international units against the OIE reference preparation using parallel-line bioassay. The assignment is transferred to working references using a software package validated under EN 17025. Calibrators are stored at −20 °C in sealed glass ampoules with desiccant. Repeated opening of the same ampoule is not permitted because moisture ingress above 1.5% w/w reduces the antigen titer. Reconstitution uses a specific diluent because phosphate-buffered saline containing 0.05% Tween 20 can alter the antigenic surface charge. The diluent must be identical to the lot used in the original potency assignment. Comparative diluent studies are run with phosphate buffer at pH 7.2 and 7.4, borate buffer at pH 8.0, and normal saline without stabilizer. Shifts of more than 0.3 pH units change the dose–response slope in the intradermal skin test. The calibrator must pass identity testing by SDS-PAGE with silver staining and reactivity against monospecific positive serum from experimentally challenged equids. Batch-to-batch variance in crude antigen production is monitored by size-exclusion HPLC with UV detection at 280 nm. The target profile includes a predominant peak with molecular weight above 10 kDa and no free media components above 5% by peak area. If a tablet, capsule, granule, or premix claim is evaluated for the API, the same potency calibrator cannot be transferred directly because the matrix effect of lactose, magnesium stearate, or corn starch on antigenic recovery has not been characterized. Published data for this specific configuration is limited; therefore any solid oral matrix would require a matrix-specific extraction and potency verification before use in diagnostic or research applications.

Tablets, Capsules, Granules, and Premix Are Excluded by Current Veterinary Pharmacopoeial Monographs

No validated therapeutic or diagnostic indication exists for oral solid dosage forms of Mallein Veterinary Grade API. The antigenic protein fraction is denatured at gastric pH below 2.0 and is further degraded by pepsin and pancreatic trypsin at pH 7.8–8.2. Intact antigen absorption across the intestinal epithelium has not been demonstrated in peer-reviewed pharmacokinetic studies. Tablets, capsules, granules, and premix would require direct compression or wet granulation. The heat generated by tableting above 30 °C can reduce antigenic reactivity. Dust exposure during blending and compression presents a sensitization risk for operators. A containment level equivalent to OEB 3 or higher is ordinarily required for dried biological antigens. The dry API is not free-flowing enough for direct compression without flow aids. Granulation with aqueous binders introduces moisture that initiates degradation during tray drying unless inlet air temperature is kept below 40 °C and final moisture is controlled below 2.0% w/w with USP <921> verification. Premix applications in feed are not supported because the antigen is not stable through pelleting at 70–85 °C and because no oral diagnostic or prophylactic claim is recognized by the OIE Terrestrial Manual. Capsules present a lower compression stress than tablets but still require the API to remain stable in a filled dry state for the intended shelf life. No regulatory monograph defines such a presentation. Where a commercial product listing includes tablets, capsules, granules, or premix formats, the technical justification should state that published data for this specific configuration is limited and that the formats are not authorized for oral use. This limitation is a regulatory and biophysical boundary rather than a formulation variable that can be resolved by typical excipient selection.